Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents

Toxicological Sciences

Volumn 25, Issue 2, 1995, Pages 201-217

  Kedderis, Lorrene Buckley ^a   Bozigian, Haig P ^a   Kleeman, James M ^a   Hall, Robert L ^a   Palmer, Thomas E ^a   Harrison, Steadman D ^a   Susick, Robert L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PROTEIN KINASE C INHIBITOR; SAFINGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DOG; FEMALE; HEMOLYSIS; HISTOPATHOLOGY; HYPOACTIVITY; INTRAVENOUS DRUG ADMINISTRATION; JAUNDICE; LEUKOPENIA; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; RAT; TESTIS; THROMBOCYTOPENIA;

ANIMAL; CISPLATIN; CYCLOPHOSPHAMIDE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HEMOLYSIS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY TUBULES; LIVER; MALE; NECROSIS; PROTEIN KINASE C; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPHINGOSINE; TESTIS;

EID: 77957184531     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/25.2.201     Document Type: Article

References (28)

1. Adams, L. M., Cofield, D.J., Seldin, J. C., Kitchen, P. A., Harrison, S. D., and Darges, J. W. (1993a). Effect of the protein kinase C (PKQ inhibitor SPC-100270 on drug accumulation and cytotoxicity in drug resistant and sensitive tumor cells in vitro). Proc. Am. Assoc. Cancer Res., 34, 410.
2. Adams, L. M., Dykes, D., Harrison, S. D., Saleh, J., and Saah, L. (1993b). Combined effect of the chemopotentiator SPC-100270, a protein kinase C (PK.C) inhibitor, and doxorubicin (DOX) or cisplatin (CIS) on murine isografts and human tumor xenografts. Proc. Am. Assoc. Cancer Res., 34, 410.
3. Calabresi, P., and Chabner, B. A. (1990). Antineoplastic agents. In The Pharmacologic Basis of Therapeutics (A. G. Gilman, T. W. Rail, A. S. Nies, and P. Taylor, Eds.), 8th ed., pp. 1209-1263. Permagon Press, New York.
4. Cappelli, V., Moggio, R., Monti, E., Paracchini, L., Piccinini, F., and Reggiani, C. (1989). Reduction in muofibrillar ATPase activity and isomyosin shift in delayed doxorubicin cardiotoxicity. J Mol. Cell Cardiol., 21, 93-101.
5. Chambers, T. C., McAvoy, E. M., Jacobs, J. W., and Elion, G. (1990). Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J. Biol Chem., 265, 7679-7686.
6. Daugaard, G., Abildgaard, U., Larsen, S., Holstein-Rathlou, N-H., Amtorp, O., Olesen, H. P., and Leyssac, P. P. (1987). Functional and histopathological changes in dog kidneys after administration of cisplatin. Renal Physiol. Basel 10, 54-64.
7. DeVore, R. F., Corbett, A. H., and Osheroff, N. (1992). Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: Effects of enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide. Cancer Res., 52, 2156-2161.
8. Dunnett, C. W. (1964). New tables for multiple comparisons with a control. Biometrics 20, 482-491.
9. Erlichman, C., Moore, M., Thiessen, J. J., Kerr, I. G., Walker, S., Goodman, P., Bjamason, G., DeAngelis, C., and Bunting, P. (1993). Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res., 53, 4837-4842.
10. Ford, J. M., and Hait, W. N. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155-192.
11. Freund, R. J. (1989). Some additional features of contrasts. SUGIProc., 14, 42-50.
12. Games, P. A., and Howell, J. F. (1976). Pairwise multiple comparisons procedures with unequal N’s and/or variances: A Monte Carlo study. J. Ed Stat., 1, 113-125.
13. Gollapudi, S., Patel, K., Jain, V., and Gupta, S. (1991). Protein kinase C modulates P-glycoprotein-mediated drug efflux in multidrug resistant murine leukemic P388/ADR cells. Proc. Am. Assoc. Cancer Res., 32, 369.
14. Hannun, Y., and Bell, R. (1987). Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem., 261, 12604-12609.
15. Herbert, M. E., Greenberg, M. L., Chaffee, S., Grauatt, L., Hershfield, M. S., Elion, G. B., and Kurtzberg, J. (1991). Pharmacologic purging of malignant T cells from human bone marrow using 9-β-D-arabinofuran-osylguanine. J. Transplantation 52, 634-640.
16. Ido, M., Asao, T., Sakurai, M., Inagaki, M., Saito, M., and Hidaka, H. (1986). An inhibitor of protein kinase C, l-5-isoquinolinylsulfonyl-2- methylpiperazine H-7, inhibits TPA-induced reduction of vincristine uptake from P388 murine leukemia cells. Leukemia Res., 10, 1063-1069.
17. Kikkawa, U., and Nishizuka, Y. (1986). The role of protein kinase C in trans-membrane signaling. Annu. Rev. Cell Biol., 2, 149-178.
18. Levene, H. (1960). Robust tests for equality of variances. In Contributions to Probability and Statistics (I. Olkikn et al., Eds.), Chap. 25, pp. 278292. Stanford Univ. Press, Stanford, CA.
19. Pennock, G. D., Dalton, W. S., Roeske, W. R., Appleton, C. P., Mosley, K., Plezia, P., Miller, T. P., and Salmon, S. E. (1991). Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J. Natl. Cancer Inst., 83, 105-110.
20. Posada, J. A., McKeegan, E. M., Worthington, K. F., Morin, M. J., Jaken, S., and Tritton, T. R. (1989). Human multidrug resistant KB cells overexpress protein kinase C: Involvement in drug resistance. Cancer Commun., 1, 285-292.
21. Reece, P. A., McCall, J. T., Powis, G., and Richardson, R. L. (1984). Sensitive high-performance liquid chromatographic assay for platinum plasma ultrafiltrate. J. Chromatogr., 306, 417-423.
22. Sachs, C. W., Ballas, L., Hannun, Y., Loomis, C, Carrol, I., Bell, R., and Fine, R. (1991). Protein kinase C inhibitors increase drug accumulation and decrease resistance of multidrug resistant cell lines. Proc. Am. Assoc. Cancer Res., 32, 373.
23. Schaeppi, U., Heyman, I. A., Fleischman, R. W., Rosenkrantz, H., Ilievski, V., Phelan, R., Cooney, D. A., and Davis, R. D. (1973). cis-Dichlorodiammineplatinum (II) (NSC-119 875): Preclinical toxicologic evaluation of intravenous injection in dogs, monkeys, and mice. Toxicol. Appl. Pharmacol., 25, 230-241.
24. Seimann, D. W., Jiang, J. B., Ballas, L., and Janzen, W. (1993). Threodi-hyrosphingosine potentiates the in vivo antitumor efficacy of cisplatin and adriamycin. Proc. Am. Assoc. Cancer Res 34, 411.
25. Vander, A. J. (Ed.) (1985). Renal Physiology, pp. 46-56. McGraw-Hill, New York.
26. Villani, F., Monti, E., Piccinini, F., Favalli, L., Lanza, E., Rozza Dionigi, A., and Poggi, P. (1986). Relationship between ECG changes and myocardial morphologic alterations induced by doxorubicin in rat. Tumori 72, 339-344.
27. Winer, B. J. (1971). Design and analysis of single-factor experiments. In Statistical Principles in Experimental Design, 2nd ed., Chap. 3, pp. 149-260. McGraw-Hill, New York.
28. Yung, B. Y-M., Luo, K. J., and Hui, E. K-W. (1992). Interaction of antileukemic agents Adriamycin and Daunomycin with sphinganine on the differentiation of human leukemia cell line HL-60. Cancer Res., 52, 3593-3597.